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OBJECTIVE—To determine the contribution of liver and vis-
cera to splanchnic cortisol production in humans.
RESEARCH DESIGN AND METHODS—D4 cortisol was in-
fused intravenously; arterial, portal venous, and hepatic venous
blood was sampled; and liver and visceral fat were biopsied in
subjects undergoing bariatric surgery.
RESULTS—Ratios of arterial and portal vein D4 cortisol/corti-
soltotal (0.06  0.01 vs. 0.06  0.01) and D4 cortisol/D3 cortisol
(1.80  0.14 vs. 1.84  0.14) did not differ, indicating that no
visceral cortisol production or conversion of D4 cortisol to D3
cortisol via 11-hydroxysteroid dehydrogenase type 1 (11-
HSD-1) occurred. Conversely, ratios of both D4 cortisol to
cortisoltotal (0.05  0.01; P  0.05) and D4 cortisol to D3 cortisol
(1.33  0.11; P  0.001) were lower in the hepatic vein than in the
portal vein, indicating production of both cortisol and D3 cortisol
by the liver. The viscera did not produce either cortisol (8.1 
2.6 g/min) or D3 cortisol (0.2  0.1 g/min). In contrast, the
liver produced both cortisol (22.7  3.90 g/min) and D3 cortisol
(1.9  0.4 g/min) and accounted for all splanchnic cortisol and
D3 cortisol production. Additionally, 11-HSD-1 mRNA was
approximately ninefold higher (P  0.01) in liver than in visceral
fat. Although 11-HSD-2 gene expression was very low in
visceral fat, the viscera released cortisone (P  0.001) and D3
cortisone (P  0.01) into the portal vein.
CONCLUSIONS—The liver accounts for all splanchnic cortisol
production in obese nondiabetic humans. In contrast, the viscera
releases cortisone into the portal vein, thereby providing sub-
strate for intrahepatic cortisol production. Diabetes 58:39–45,
2009
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lthough it has been long known that glucocor-
ticoids are potent regulators of glucose, fat, and
protein metabolism, glucocorticoids have not
been thought to cause insulin resistance in
either obese or diabetic individuals because plasma con-
centrations do not differ from those present in lean
nondiabetic subjects. However, extra-adrenal conversion
of cortisone to cortisol via 11-hydroxysteroid dehydroge-
nase type 1 (11-HSD-1) can result in high local concen-
trations of cortisol. This observation focused attention on
the possibility that tissue-speciﬁc synthesis of glucocorti-
coids may contribute to the pathogenesis of insulin resis-
tance and other components of the so called “metabolic
syndrome” (1). The enzyme 11-HSD-2 (which converts
cortisol to cortisone) is present primarily in the kidney,
whereas 11-HSD-1 (which converts cortisone to cortisol)
is present in both liver and adipose tissue with in vitro
activity being greater in omental than subcutaneous fat
deposits (2–5). Inhibition (6) or knockout (7–9) of 11-
HSD-1 in mice improves hepatic insulin action and pro-
tects against obesity and hyperglycemia. Conversely,
selective overexpression of 11-HSD-1 in adipose tissue
in mice results in development of visceral obesity, hyper-
glycemia, hyperlipidemia, and hypertension (7–11).
Using a novel tracer infusion method, Andrew et al. (12)
demonstrated that infusion of [9,11,12,12-
2H4] cortisol (D4
cortisol) in fasting, nondiabetic humans resulted in the
formation of measurable amounts of plasma [9,12,12-
2H3]
cortisol (D3 cortisol). Because conversion of D4 cortisol
to D3 cortisone by 11-HSD-2 results in the loss of the 11
-deuterium and the generation of D3 cortisone that in
turn forms D3 cortisol when D3 cortisone is converted
back to cortisol, this observation provides strong experi-
mental evidence that the conversion of cortisone to corti-
sol occurs in humans (12). More recently, we used the
same method in combination with the hepatic venous and
leg catheterization techniques to determine the site(s) of
conversion of cortisone to cortisol. Those studies (13) led
to the discovery that rates of splanchnic cortisol produc-
tion in healthy nondiabetic individuals equaled or even
exceeded those produced by extrasplanchnic tissues (e.g.,
the adrenals). However, because concomitant uptake of
cortisol also occurred within the splanchnic bed, only a
small net amount of cortisol was released into the sys-
temic circulation.
Because portal venous blood was not sampled in those
studies, we could not determine the individual contribu-
tions of the viscera and the liver to splanchnic cortisol
production. We therefore addressed this question in a
chronically catheterized conscious dog model that permit-
ted simultaneous selective sampling of blood from an
artery, the portal vein, and the hepatic vein during intra-
venous infusion of D4 cortisol (14). Surprisingly, we
showed that the liver accounted for all of the splanchnic
cortisol production in the dog without discernable release
by the viscera. However, the dogs were lean, and it is
unknown if the pattern of splanchnic cortisol production
in dogs reﬂects that in humans. Therefore, it remained
possible that visceral fat releases cortisol into the portal
vein in obese humans, thereby exposing the liver to high
local glucocorticoid concentrations.
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selectively obtaining simultaneous samples of arterial,
portal venous, and hepatic venous blood during a D4
cortisol infusion in severely obese subjects undergoing
bariatric surgery. In addition, mRNA for the glucocorticoid
receptor (NR3C1), 11-HSD-1, and 11-HSD-2 was mea-
sured in liver and visceral fat obtained during surgery.
We report that the liver accounts for all of the splanch-
nic cortisol production in obese nondiabetic humans. In
contrast, there was no detectible release of cortisol into
the portal vein by the viscera. On the other hand,
although the mRNA for 11-HSD-2 in visceral fat was
very low, the viscera released cortisone into the portal
vein, thereby providing the liver with substrate for
intrahepatic cortisol production.
RESEARCH DESIGN AND METHODS
After approval from the Mayo Institutional Review Board, 10 nondiabetic
subjects (8 women and 2 men) gave informed written consent to participate in
the study. All volunteers were undergoing elective bariatric surgery via a
celiotomy and met the inclusion and exclusion criteria for the surgical
procedure. Subjects had a mean age of 52  3 years, a mean BMI of 46  3
kg/m
2, fasting plasma glucose of 97  2 mg/dl, alkaline phosphatase of 98 
15 units/l (reference range 45–115 units/l), aspartate aminotransferase (AST)
of 24  1 unit/l (reference range 8–48 units/l), and A1C of 5.2  0.5%. The liver
was biopsied during surgery. Histopathology indicated that 7 of the 10
subjects had mild steatohepatitis and that the remaining three had normal
livers. Subjects were on stable doses of thyroxine, estrogen replacement
therapy, selective serotonin reuptake inhibitor antidepressants, low-dose
thiazide, calcium channel blocker, losartan, or lipid-lowering agent at the time
of surgery.
Subjects were admitted to the Mayo Clinic Center for Translational Science
Activities Clinical Research Unit at 1700 h on the evening before the study. A
standard 10-cal/kg meal (55% carbohydrate, 30% fat, and 15% protein) was
eaten between 1730 and 1800 h.
At 0600 h on the morning of operation, an intravenous catheter was
placed in a forearm vein for the infusions. A primed, continuous infusion of
[9,11,12,12-
2H4] cortisol (0.22 mg prime, 0.19 mg/h continuous; Cambridge
Isotope Laboratories, Andover, MA) was started. Subjects then were taken to
an interventional radiology suite where a hepatic venous catheter was placed
selectively via the internal jugular vein under ﬂuoroscopic control. An artery
catheter was placed by the anesthesiologist as part of the operative procedure.
Approximately 1 h before the start of the operation, an infusion of indocyanine
green dye (Akorn, Buffalo Grove, IL) was begun via the forearm vein. During
the intraoperative period, portal venous samples were obtained by catheter-
izing a small mesenteric vein of a segment of the proximal jejunum and
threading a 3-French intravenous catheter into the portal vein (16). Two blood
samples were taken simultaneously (5 min apart) from the hepatic vein, the
portal vein, and the arterial catheter. The portal venous catheter then was
removed, and that section of mesentery and jejunum was resected as per
surgical technique (16). The hepatic venous catheter was also removed, and
the infusions of D4 cortisol and indocyanine green were discontinued.
Samples of liver and omental fat were also obtained during the operation.
Analytical techniques. All samples were placed on ice, centrifuged at 4°C,
and separated. Plasma concentrations of indocyanine green were measured
spectrophotometrically at 805 nm on the day of study as described previously
(14). All other samples were stored at 80°C until analysis.
Concentrations of hepatic venous, arterial, and portal venous cortisol; D4
cortisol; D3 cortisol; cortisone; and D3 cortisone were measured using liquid
chromatography tandem mass spectrometry as described previously (13). In
brief, methylprednisolone was added as an internal standard, and methylene
chloride was used to extract the relevant steroids. The dried extract was then
reconstituted and injected into a liquid chromatography tandem mass spec-
trometer. Cortisol, D4 cortisol, and D3 cortisol ions were generated with
electrospray source in positive mode and were detected with multiple
reactions monitoring the speciﬁc transitions for m/z 363 to 121, 367 to 121, and
366 to 121, respectively. This approach enabled simultaneous monitoring of
both the pronated parent ion and fragmented daughter ion, thereby increasing
speciﬁcity.
Liver and omental fat tissue were quick frozen with liquid nitrogen and
stored in dry ice. Then 150-mg (liver) and 200-mg (fat) sections were weighed
and lysed using an appropriate amount of Qiazol Lysis Reagent (Qiagen,
Valencia, CA) and mechanical homogenization. Qiazol homogenates were
used to isolate total RNA using automated Qiagen RNeasy technology on the
Qiagen BioRobot 3000. Reverse transcription and PCR were performed at
standard temperatures using the Invitrogen SuperScript III Platinum One-Step
Quantitative RT-PCR System (Invitrogen, Carlsbad, CA). All samples were
analyzed for RNA integrity using the Agilent 2100 Bioanalyzer. The samples
were run in triplicate. Data analysis was performed by ﬁrst normalizing all
data to the Total Human Reference RNA standard curve for each gene to
achieve a relative amount of target RNA (ng). Then, each sample was
normalized to the average amount of RNA (ng) for the three control
housekeeper genes (PPIA, RPLPO, and RPL19; Clontech, Mountain View,
CA). This approach permitted assessment of relative expression between
samples of interest for a speciﬁc target gene; however, comparison of absolute
amounts of expression between genes was not possible.
Calculations. Portal and splanchnic plasma ﬂows were calculated by divid-
ing the indocyanine green infusion rate by the arterial-to-portal venous and
arterial-to-hepatic venous concentration gradient of the dye, respectively
(13,14). Hepatic artery plasma ﬂow was calculated by subtracting portal
plasma ﬂow from splanchnic plasma ﬂow.
Fractional extraction of D4 cortisol across the liver was calculated as
Liver ER D4cort

	AD4cort  HAPF
  	PoVD4cort  PoV PF
  	HVD4cort  Liver PF

	AD4cort  HAPF
  	PoVD4cort  PoV PF
 
(1)
where ER is the extraction ratio, A is arterial, HV is hepatic venous, PoV is
portal venous, HAPF (ml/min) is hepatic artery plasma ﬂow, PoV PF (ml/min)
is portal venous plasma ﬂow, and Liver PF (ml/min) is liver plasma ﬂow.
Fractional extraction across the viscera was calculated as
Visceral ER D4cort 
AD 4 cort  PoV D4cort
AD 4 cort
(2)
Viscera net cortisol balance was calculated as
NVisceral CB  	ATcort  PoVTcort
  PoV PF (3)
where N is net and CB is cortisol balance and Tcort (referred to as cortisoltotal
in the text) is the sum of unlabeled cortisol, D4 cortisol, and D3 cortisol.
Liver net cortisol balance was calculated as
NLiverCB  	ATcort  HAPF
  	PoVTcort  PoV PF

  	HVTcort  Liver PF)
(4)
Liver cortisol uptake was calculated as
Liver CU  	ATcort  Liver PF
  Liver ER D4cort (5)
where CU is cortisol uptake.
Visceral cortisol uptake was calculated as
Visceral CU  	PoVTcort  PoV PF
  Visceral ER D4cort (6)
Visceral and liver cortisol productions were calculated
Liver CP  NLiver CB  Liver CU (7)
Visceral CP  NVisceral CB  Visceral CU (8)
For the sake of clarity of presentation, hepatic cortisol and D3 cortisol
productions are expressed as positive numbers in the ﬁgures and the text.
D3 visceral and liver net balance, uptake, and production were calculated
using Eqs. 3–8, except that D3 cortisol concentration was substituted for total
cortisol concentration.
Statistical analyses. Data in the text and ﬁgures are expressed as means 
SEM. Rates are expressed as micrograms per minute. Responses were
determined by averaging the results of the two sets of samples taken 5 min
apart. Student’s paired t test was used to determine whether rates differed
across the viscera and liver. ANOVA also was used to compare results among
the artery, portal vein, and hepatic vein. A P value of 0.05 was considered as
statistically signiﬁcant.
RESULTS
Arterial, portal venous, and hepatic venous total
cortisol, D4 cortisol, and D3 cortisol concentrations.
Portal venous cortisol concentrations were lower (P 
0.001) than arterial cortisol concentrations (17.6  2.3 vs.
20.3  2.3 g/dl), indicating net uptake of cortisol by the
viscera. Hepatic venous cortisol concentrations (16.7 
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differ from portal venous cortisol concentrations (Fig. 1).
Portal venous D4 cortisol concentrations (0.84  0.10
g/dl) were lower (P  0.01) than arterial D4 cortisol
concentrations (0.97  0.11 g/dl) but greater (P  0.001)
than hepatic venous D4 cortisol concentrations (0.73 
0.10 g/dl), indicating 13  2 and 15  2% extraction of
cortisol by the viscera and the liver, respectively.
Portal venous D3 cortisol concentrations were lower
(P  0.01) than arterial D3 cortisol concentrations (0.49 
0.07 vs. 0.57  0.09 g/dl), indicating net uptake of D3
cortisol by the viscera. Hepatic venous D3 cortisol con-
centrations (0.60  0.10 g/dl) were greater (P  0.05)
than portal venous concentrations but did not differ from
arterial cortisol concentrations.
Arterial, portal venous, and hepatic venous total
cortisone and D3 cortisone concentrations. Portal
venous cortisone concentrations were higher (P  0.001)
than arterial cortisone concentrations (3.55  0.44 vs.
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the viscera. Hepatic venous cortisone concentrations
(0.10  0.03 g/dl) were lower (P  0.001) than both
arterial and portal venous cortisone concentrations, indi-
cating net extraction of cortisone by the liver (Fig. 2).
A similar pattern was observed for D3 cortisone. Portal
venous D3 cortisone concentrations were higher (P 
0.05) than arterial D3 cortisone concentrations (0.16 
0.05 vs. 0.06  0.02 g/dl), indicating net release by the
viscera. Hepatic venous D3 cortisone concentrations
(0.00  0.00 g/dl) were lower (P  0.05) than portal
venous concentrations, indicating net extraction of D3
cortisone by the liver.
Plasma D4 cortisol–to–cortisoltotal and D4 cortisol–
to–D3 cortisol ratios. The plasma ratio of D4 cortisol to
cortisoltotal only is inﬂuenced by a change in the rate of
cortisol production because both D4 cortisol and cortisol
are cleared in parallel. The plasma ratio of D4 cortisol to
cortisoltotal was identical in the artery and portal vein
(0.06  0.01 vs. 0.06  0.01), indicating that the viscera did
not produce cortisol. In contrast, the ratio of D4 cortisol to
cortisoltotal in the hepatic vein (0.05  0.01) was lower
(P  0.05) than that in the portal vein and artery, indicat-
ing cortisol production by the liver (Fig. 3).
Similarly, the ratio of D4 cortisol to D3 cortisol did not
differ in the artery and the portal vein (1.80  0.14 vs.
1.84  0.14) but was lower (P  0.001) in the hepatic vein
(1.33  0.11) than in the portal vein, indicating generation
of D3 cortisol from D4 cortisol via the 11 -HSD-1 pathway
in the liver but not in the viscera.
Visceral and liver net cortisol balance, cortisol up-
take, and cortisol production. Arterial and portal ve-
nous plasma ﬂow averaged 77  11 and 983  94 ml/min,
respectively. Net visceral cortisol balance (26.94  4.81
g/min) was positive, indicating net cortisol uptake across
the viscera. In contrast, net cortisol balance across the
liver did not differ from zero (11.87  8.08 g/min).
Visceral cortisol uptake tended to be lower (P  0.07) than
liver cortisol uptake (18.84  2.42 vs. 34.52  7.32 g/min).
Cortisol production by the liver averaged 22.65  3.85
g/min, accounting for all cortisol produced within the
splanchnic bed. No cortisol was produced by the viscera
(8.10  2.62 g/min) (Figs. 4 and 5).
Viscera and liver net D3 cortisol balance, D3 corti-
sol uptake, and D3 cortisol production. D4 cortisol is
converted to D3 cortisone by 11-HSD-2, which in turn
is converted to D3 cortisol by 11-HSD-1. Therefore,
measurement of D3 cortisol production provides an
index of ﬂux through the 11-HSD-1 pathway. Net
balance of D3 cortisol across the viscera averaged 0.8 
0.2 g/min, indicating net uptake. Net D3 cortisol bal-
ance across the liver averaged 1.0  0.3 g/min,
indicating there was net release of D3 cortisol. Uptake
of D3 cortisol by the visceral and the liver averaged
0.6  0.1 and 0.9  0.2 g/min, respectively. Whereas
signiﬁcant amounts (P  0.001 vs. zero production) of
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FIG. 5. Schematic representation of visceral and liver cortisol and D3 cortisol uptake and production. LCP, liver cortisol production; LCU, liver
cortisol uptake; VCP, viscera cortisol production; VCU, viscera cortisol uptake.
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g/min), no D3 cortisol was produced by the viscera
(0.2  0.1 g/min) (Figs. 5 and 6).
Gene expression of glucocorticoid receptor, 11-
HSD-1, and 11-HSD-2 in visceral fat and the liver.
Gene expression (mRNA) for the glucocorticoid receptor
(NR3C1) did not differ in the liver and visceral fat. In
contrast, 11-HSD-1 mRNA expression was approxi-
mately ninefold higher (P  0.01) in the liver than visceral
fat. 11-HSD-2 mRNA expression was low but detectible
(0.5 relative ng of human reference RNA standard curve)
in both liver and visceral fat (Fig. 7).
DISCUSSION
These data indicate that the liver accounts for virtually all
splanchnic cortisol production in obese humans. Although
11-HSD-1 gene expression is present in visceral fat,
albeit at levels far lower than in the liver, the viscera does
not appear to release cortisol into the portal vein nor does
it convert D4 cortisol to D3 cortisol. In contrast, despite
very low expression of mRNA for 11-HSD-2 in visceral
fat, the viscera releases cortisone and D3 cortisone (de-
rived from D4 cortisol) into the portal vein, thereby
providing substrate for intrahepatic cortisol production.
The conclusion that the liver accounts for virtually all
splanchnic cortisol production in obese humans is con-
sistent with what we previously observed in chronically
catheterized lean dogs (17). These observations differ
from the report by Walker and colleagues (18) that
visceral fat accounts for approximately two-thirds and
the liver approximately one-third of splanchnic cortisol
production. However, as appropriately pointed out by
those authors (18), this conclusion was based on esti-
mates rather than direct measurement of visceral and
liver cortisol production. The lack of detectible cortisol
release into the portal vein by the viscera in the present
experiments does not exclude the possibility that corti-
sol is generated within visceral adipocytes and that the
resultant high intracellular concentrations do not equil-
ibrate with the extracellular space; however, because
cortisol diffuses readily across plasma membranes, we
believe this to be unlikely. The subjects in the present
experiments were undergoing bariatric surgery. There-
fore, it is possible that visceral 11-HSD-1 activity was
inhibited by anesthesia. However, the fact that substan-
tial cortisone-to-cortisol conversion occurred within the
liver and the rates of splanchnic cortisol production
observed in the present experiments are comparable
with those observed in our previous experiments in the
absence of anesthesia argue against this possibility (13).
Calculation of rates of cortisol production requires
measurement of blood ﬂow. Therefore, variability in blood
ﬂow could have confounded detection of the release of
small amounts of cortisol by the viscera. However, the
virtually identical tracer-to-tracee ratios (i.e., D4 cortisol
to cortisoltotal and D4 cortisol to D3 cortisol) across the
viscera provide blood ﬂow– and model-independent evi-
dence that there was no release of cortisol by the viscera
into the portal vein. Cortisol could have been released by
visceral fat into the portal vein that was not detected
because of dilution by blood ﬂow from other tissues within
the viscera that did not release cortisol. Because the
subjects were severely obese and therefore had massive
amounts of visceral fat, if such release did occur, it was
not sufﬁcient to increase portal cortisol delivery to the
liver in these subjects and therefore is extremely unlikely
to do so in less obese humans. Perhaps more importantly,
cortisol production was measured across the entire vis-
cera. Different patterns of conversion could occur in
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cortisone to cortisol via 11-HSD-1 reductase and gut
epithelium could convert cortisol to cortisone via 11-
HSD-2. However, conversion of cortisol to cortisone in one
tissue (e.g., gut) does not inﬂuence calculation of visceral
cortisol or D3 cortisol production in another, because this
would be reﬂected by an increase in fractional extraction
of D4 cortisol, which in turn is used to calculate cortisol
production (see Eqs. 6 and 8).
It should be noted that although none of the subjects
were known to have diabetes, only fasting glucose con-
centrations were measured. Therefore, it is possible (in
fact likely) that at least some of the subjects would have
been diagnosed as having diabetes if two oral glucose
tolerance tests had been performed. However, because
visceral cortisol production was negligible in all subjects,
we do not believe that oral glucose tolerance test status
would change our conclusions.
Consistent with previous reports, 11-HSD-2 mRNA
was barely detectible in visceral fat (15). We therefore
were surprised to ﬁnd that there was net release of
cortisone by the viscera into the portal vein. There also
was net release of D3 cortisone derived from the D4
cortisol entering the viscera. The increment in cortisone
between the artery and portal vein averaged 21 g/l.
Because portal blood ﬂow averaged 1 l/min, this
resulted in 21 g/min cortisone being delivered to the
liver, which essentially equaled the 23 g/min cortisol
produced by the liver. Although rates of D3 cortisone
release by the viscera (1.0 g/min) and hepatic D3
cortisol production by the liver (1.9 g/min) were not
matched as closely, the potential contribution of viscer-
ally derived D3 cortisone to hepatic D3 cortisol produc-
tion still was substantial. If this observation is
conﬁrmed in subsequent studies, then it would suggest
that whereas the viscera do not increase hepatic cortisol
exposure by releasing cortisol into the portal vein,
cortisone release could increase cortisol concentrations
within the liver by providing the substrate for hepatic
11-HSD-1. If so, this would be particularly intriguing,
because the reduction in portal cortisol by conversion
of cortisol to cortisone by the viscera would decrease
local cortisol concentrations in areas of the liver where
11-HSD-1 is not expressed but increase concentra-
tions in areas where 11-HSD-1 is expressed (e.g., the
periportal region) (19). The observation that substantial
conversion of cortisol to cortisone occurred in the
viscera despite the fact that 11-HSD-2 message was
barely detectible in visceral fat is intriguing. However,
because 11-HSD-1 is a bidirectional enzyme and be-
cause substantial amounts of mRNA for this enzyme
were present in omental fat, it could account for most if
not all of visceral cortisol to cortisone conversion (1,2).
In conclusion, the liver accounts for virtually all
splanchnic cortisol production in obese, nondiabetic hu-
mans. There is no evidence for visceral cortisol production
whether measured as dilution of tracee-to-tracer ratios
across the viscera or by calculation of rates of production
of visceral cortisol or D3 cortisol. On the other hand, the
viscera release cortisone into the portal vein, thereby
providing the liver additional substrate for intrahepatic
cortisol production. The extent to which hepatic cortisol
production is regulated by the rate of cortisone delivery
and/or other factors remains to be determined.
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